The burden of neovascular age-related macular degeneration: a patient’s perspective
Kimberly L Spooner,1,2 Cleopatra T Mhlanga,1 Thomas H Hong,1 Geoffrey K Broadhead,1 Andrew A Chang1,2 1Sydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia Purpose: To quantify the burden and quality of life of...
Guardado en:
Autores principales: | , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c574bc2573a74331bfdb03eefea0a587 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:c574bc2573a74331bfdb03eefea0a587 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:c574bc2573a74331bfdb03eefea0a5872021-12-02T08:36:31ZThe burden of neovascular age-related macular degeneration: a patient’s perspective1177-5483https://doaj.org/article/c574bc2573a74331bfdb03eefea0a5872018-12-01T00:00:00Zhttps://www.dovepress.com/the-burden-of-neovascular-age-related-macular-degeneration-a-patients--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Kimberly L Spooner,1,2 Cleopatra T Mhlanga,1 Thomas H Hong,1 Geoffrey K Broadhead,1 Andrew A Chang1,2 1Sydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia Purpose: To quantify the burden and quality of life of patients and their caregivers in a cohort of patients with neovascular age-related macular degeneration (nAMD) in an Australian clinical setting.Methods: A total of 103 patients undergoing anti-vascular endothelial growth factor (VEGF) therapy for nAMD were asked to complete questionnaires relating to the financial and time burdens of nAMD.Results: All patients completed the questionnaires. Loss in productivity due to attendance of appointments was 4.4±1.7 hours per month, with additional time lost by caregivers. Financial strain was incurred by direct medical costs associated with intravitreal assessment and injections at an average of AU$199.2±$83.1 per month. Indirect costs incurred averaged $64.8±$79.7 per month. Qualitative indirect costs due to loss of productivity for the patient, unpaid caregivers, and loss of productivity due to premature mortality were also a considerable burden. Overall mean Visual Function Questionnaire and EuroQol 5D-3L scores were correlated with visual acuity and demonstrated patients’ subjective decline in quality of vision.Conclusion: Management of nAMD carries a substantial burden on patients and caregivers. These results provide important information in understanding the effect of anti-VEGF therapy among patients with nAMD. Together with the quality-of-life burden on the patients, the management of nAMD has a significant societal impact. Keywords: burden, treatment, anti-VEGF, age-related macular degeneration, Australia, patient perspectiveSpooner KLMhlanga CTHong THBroadhead GKChang AADove Medical PressarticleBurdentreatmentanti-VEGFage-related macular degenerationAustraliaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 2483-2491 (2018) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Burden treatment anti-VEGF age-related macular degeneration Australia Ophthalmology RE1-994 |
spellingShingle |
Burden treatment anti-VEGF age-related macular degeneration Australia Ophthalmology RE1-994 Spooner KL Mhlanga CT Hong TH Broadhead GK Chang AA The burden of neovascular age-related macular degeneration: a patient’s perspective |
description |
Kimberly L Spooner,1,2 Cleopatra T Mhlanga,1 Thomas H Hong,1 Geoffrey K Broadhead,1 Andrew A Chang1,2 1Sydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia Purpose: To quantify the burden and quality of life of patients and their caregivers in a cohort of patients with neovascular age-related macular degeneration (nAMD) in an Australian clinical setting.Methods: A total of 103 patients undergoing anti-vascular endothelial growth factor (VEGF) therapy for nAMD were asked to complete questionnaires relating to the financial and time burdens of nAMD.Results: All patients completed the questionnaires. Loss in productivity due to attendance of appointments was 4.4±1.7 hours per month, with additional time lost by caregivers. Financial strain was incurred by direct medical costs associated with intravitreal assessment and injections at an average of AU$199.2±$83.1 per month. Indirect costs incurred averaged $64.8±$79.7 per month. Qualitative indirect costs due to loss of productivity for the patient, unpaid caregivers, and loss of productivity due to premature mortality were also a considerable burden. Overall mean Visual Function Questionnaire and EuroQol 5D-3L scores were correlated with visual acuity and demonstrated patients’ subjective decline in quality of vision.Conclusion: Management of nAMD carries a substantial burden on patients and caregivers. These results provide important information in understanding the effect of anti-VEGF therapy among patients with nAMD. Together with the quality-of-life burden on the patients, the management of nAMD has a significant societal impact. Keywords: burden, treatment, anti-VEGF, age-related macular degeneration, Australia, patient perspective |
format |
article |
author |
Spooner KL Mhlanga CT Hong TH Broadhead GK Chang AA |
author_facet |
Spooner KL Mhlanga CT Hong TH Broadhead GK Chang AA |
author_sort |
Spooner KL |
title |
The burden of neovascular age-related macular degeneration: a patient’s perspective |
title_short |
The burden of neovascular age-related macular degeneration: a patient’s perspective |
title_full |
The burden of neovascular age-related macular degeneration: a patient’s perspective |
title_fullStr |
The burden of neovascular age-related macular degeneration: a patient’s perspective |
title_full_unstemmed |
The burden of neovascular age-related macular degeneration: a patient’s perspective |
title_sort |
burden of neovascular age-related macular degeneration: a patient’s perspective |
publisher |
Dove Medical Press |
publishDate |
2018 |
url |
https://doaj.org/article/c574bc2573a74331bfdb03eefea0a587 |
work_keys_str_mv |
AT spoonerkl theburdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective AT mhlangact theburdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective AT hongth theburdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective AT broadheadgk theburdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective AT changaa theburdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective AT spoonerkl burdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective AT mhlangact burdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective AT hongth burdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective AT broadheadgk burdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective AT changaa burdenofneovascularagerelatedmaculardegenerationapatientrsquosperspective |
_version_ |
1718398458277134336 |